Artiva's cell therapy approach to autoimmune conditions is unique because it is NK cell based, donor derived, and there is no engineering of the cells - they believe the benefit is already in the data
- 1 day ago
- 1 min read
CEO Fred Aslan walks us through this unique program and its potential advantages, which include that it can be administered in the community setting and can also be redosed if necessary. A 350 patient randomized registration trial in rheumatoid arthritis will be underway this year.
Coverage brought to you by











.png)